5 Most Profitable Biotech Stocks to Buy Now

2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a $875 price target. The assessment followed an Integrated Oncology Day event at the Sylvester Cancer Center in Miami. The event included discussions on oncology therapies and ophthalmology with key experts from the Bascom Palmer Eye Institute.

One of the event’s main themes revolved around optimism about BCMA T-cell engagers transitioning into second-line treatment with MAJESTEC-3 results. Leading experts claimed they were not worried about sequencing CAR-T therapy following BCMA T-cell engagers.

Meanwhile, Cantor Fitzgerald maintained its Overweight rating and $800 price target for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on April 8. The firm predicted that near-term fianlimab data will continue to dominate first-quarter 2026 findings.

Cantor Fitzgerald isn’t expecting data before the Q1 2026 earnings call. For the quarter, the firm expects a lower-impact print, led by a broadly in-line and well-anticipated Eylea HD result and a minor shortfall for Dupixent in what it calls the notoriously difficult first quarter.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a prominent biopharmaceutical company that discovers, develops, and commercializes medicines for a variety of diseases, including cancer, eye disorders, and allergies.